[Clinical and therapeutic evaluation of a new antilipemic substance].
Thirty male patients with hypersyslipidemia (hyperlipemia involving both total lipids and the different lipemic fractions) were treated for 60 days with clofibrate at the dosage of 2 g/day in two administrations. Following a 15-day interval, treatment was resumed with lysine clofibrate, at the same dosage, for 2 subsequent months. At the end of both treatments, it was recorded a clear-cout reduction in the levels of cholesterol, triglycerides, total lipids and lipoproteins. When comparing the effectiveness of the two treatments, we notice that the activity of the two products is identical, though the effects of lysine clofibrate was more precociously evident than that of clofibrate. The results obtained are particularly interesting: equal doses of the drugs were administered, yet the clofibric acid contained in lysine clofibrate is much less than that cointained in clofibrate. As far as tolerance is concerned, 5 cases treated with clofibrate declared to have suffered of gastro-enteric disturbances, while with lysine clofibrate, only 1 case showed side effects.
D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; C028054:lysine clofibrate; D002784:Cholesterol; D002994:Clofibrate
Valutazione clinica e terapeutica di una nuova sostanza ad effetto ipolipemizzante.